+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Dystrophin (DMD) - Drugs In Development, 2021

  • ID: 5359589
  • Drug Pipelines
  • June 2021
  • Region: Global
  • 161 pages
  • Global Markets Direct

FEATURED COMPANIES

  • Alpha Anomeric
  • Astellas Gene Therapies
  • Code Biotherapeutics Inc
  • Daiichi Sankyo Co Ltd
  • Dystrogen Therapeutics SA
  • Editas Medicine Inc
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

According to the recently published report 'Dystrophin - Drugs In Development, 2021'; Dystrophin (DMD) pipeline Target constitutes close to 57 molecules. Out of which approximately 51 molecules are developed by companies and remaining by the universities/institutes.

Dystrophin (DMD) - Dystrophin is a cytoplasmic protein. It anchors the extracellular matrix to the cytoskeleton via F-actin. It acts as ligand for dystroglycan. It acts as component of the dystrophin-associated glycoprotein complex which accumulates at the neuromuscular junction and at a variety of synapses in the peripheral and central nervous systems and has a structural function in stabilizing the sarcolemma.

The report 'Dystrophin - Drugs In Development, 2021' outlays comprehensive information on the Dystrophin (DMD) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Dystrophin (DMD) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Filing rejected/Withdrawn, Phase III, Phase II, IND/CTA Filed, Preclinical and Discovery stages are 1, 3, 6, 1, 31 and 9 respectively. Similarly, the universities portfolio in Phase I and Preclinical stages comprises 1 and 5 molecules, respectively. Report covers products from therapy areas Genetic Disorders and Musculoskeletal Disorders which include indications Duchenne Muscular Dystrophy, Alport Syndrome and Muscular Dystrophy.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Dystrophin (DMD)
  • The report reviews Dystrophin (DMD) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Dystrophin (DMD) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Dystrophin (DMD) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Dystrophin (DMD) targeted therapeutics
Reasons to Buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Dystrophin (DMD)Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Dystrophin (DMD) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Alpha Anomeric
  • Astellas Gene Therapies
  • Code Biotherapeutics Inc
  • Daiichi Sankyo Co Ltd
  • Dystrogen Therapeutics SA
  • Editas Medicine Inc
  • MORE
  • Introduction
  • Dystrophin (DMD) - Overview
  • Dystrophin (DMD) - Therapeutics Development
  • Dystrophin (DMD) - Therapeutics Assessment
  • Dystrophin (DMD) - Companies Involved in Therapeutics Development
  • Dystrophin (DMD) - Drug Profiles
  • Dystrophin (DMD) - Dormant Products
Dystrophin (DMD) - Discontinued Products
  • Dystrophin (DMD) - Product Development Milestones
  • Appendix
List of Tables
  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Indication, 2021
  • Number of Products under Development by Companies, 2021
  • Products under Development by Companies, 2021
  • Number of Products under Investigation by Universities/Institutes, 2021
  • Products under Investigation by Universities/Institutes, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Pipeline by Alpha Anomeric, 2021
  • Pipeline by Astellas Gene Therapies, 2021
  • Pipeline by Code Biotherapeutics Inc, 2021
  • Pipeline by Daiichi Sankyo Co Ltd, 2021
  • Pipeline by Dystrogen Therapeutics SA, 2021
  • Pipeline by Editas Medicine Inc, 2021
  • Pipeline by Evox Therapeutics Ltd, 2021
  • Pipeline by FibroGenesis LLC, 2021
  • Pipeline by MyoGene Bio LLC, 2021
  • Pipeline by Myosana Therapeutics Inc, 2021
  • Pipeline by Nippon Shinyaku Co Ltd, 2021
  • Pipeline by OliPass Corporation, 2021
  • Pipeline by Pepgen Ltd, 2021
  • Pipeline by Vertex Pharmaceuticals Inc, 2021
  • Pipeline by Wave Life Sciences Ltd, 2021
  • Dormant Projects, 2021
  • Discontinued Products, 2021
List of Figures
  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Top 10 Indications, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021
Note: Product cover images may vary from those shown
  • Alpha Anomeric
  • Astellas Gene Therapies
  • Code Biotherapeutics Inc
  • Daiichi Sankyo Co Ltd
  • Dystrogen Therapeutics SA
  • Editas Medicine Inc
  • Evox Therapeutics Ltd
  • FibroGenesis LLC
  • MyoGene Bio LLC
  • Myosana Therapeutics Inc
  • Vertex Pharmaceuticals Inc
  • Wave Life Sciences Ltd
Note: Product cover images may vary from those shown
Adroll
adroll